
Bill Hinshaw
President & Chief Executive Officer
We are a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using endogenous metabolic modulator (EMM) compositions. EMMs fundamentally impact and regulate metabolism, controlling many of the biological functions. At Axcella, we are seeking to unlock the full potential of EMMs by combining a deep understanding of biological pathways with recent advances in systems biology and machine learning. The end result: Multi-targeted EMM compositions with the potential to address the unmet medical needs of patients with a range of complex conditions.
President & Chief Executive Officer
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Legal Officer and Corporate Secretary
Senior Vice President, Strategic Operations
Board ChairmanExecutive Partner, Flagship Pioneering
Chief Financial Officer, Bluebird Bio
Head of Global Business Development and M&A at Nestlé Health Science
President & Chief Executive Officer
Harry E. Figgie Professor of Business Administration, Harvard Business School
Founder, CMR Pharma Consulting
Senior Partner, Flagship Pioneering
Board Member and Advisor to the Life Science Industry
Adjunct Professor, University of California San Francisco
Senior Partner, Flagship Pioneering, CEO of Repertoire and Founding CEO of FL84
Whether you are a potential employee, business partner or investor, we want to hear from you.
Distinguished Service Professor & Higginson Professor of Physiology and Medicine, Harvard Medical School
Director, Sarah W. Stedman Nutrition and Metabolism Center Director, Duke Molecular Physiology Institute
Chief Executive Officer, Kallyope
Cleveland Family Professor of Pediatric Research Professor of Human Genetics University of Pittsburgh
Senior Partner, Flagship Pioneering